Q3 EPS Estimate for Niagen Bioscience Reduced by Analyst

Niagen Bioscience, Inc. (NASDAQ:NAGE) – Equities researchers at HC Wainwright lowered their Q3 2026 EPS estimates for Niagen Bioscience in a report issued on Wednesday, August 5th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $0.02 per share for the quarter, down from their prior estimate of $0.08. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Niagen Bioscience’s current full-year earnings is $0.21 per share. HC Wainwright also issued estimates for Niagen Bioscience’s Q1 2027 earnings at $0.03 EPS, Q2 2027 earnings at $0.03 EPS, Q3 2027 earnings at $0.04 EPS and Q4 2027 earnings at $0.05 EPS.

A number of other analysts have also commented on NAGE. Canaccord Genuity Group dropped their price target on Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Wall Street Zen downgraded shares of Niagen Bioscience from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Roth Capital restated a “buy” rating on shares of Niagen Bioscience in a report on Wednesday. Freedom Capital raised shares of Niagen Bioscience to a “strong-buy” rating in a research report on Monday, July 6th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Niagen Bioscience currently has an average rating of “Buy” and an average price target of $10.33.

Niagen Bioscience Stock Performance

NAGE opened at $2.96 on Thursday. The stock has a market capitalization of $235.73 million, a PE ratio of 16.45 and a beta of 2.09. The stock’s 50 day moving average price is $3.41 and its 200-day moving average price is $4.34. Niagen Bioscience has a 52-week low of $2.87 and a 52-week high of $11.29.

Niagen Bioscience (NASDAQ:NAGE) last posted its earnings results on Tuesday, August 4th. The company reported $0.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.01. Niagen Bioscience had a net margin of 12.39% and a return on equity of 18.31%. The company had revenue of $29.78 million during the quarter, compared to analyst estimates of $29.95 million.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. SteelPeak Wealth LLC bought a new stake in shares of Niagen Bioscience during the 1st quarter valued at $14,875,000. Arrowstreet Capital Limited Partnership lifted its position in Niagen Bioscience by 47.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,378,437 shares of the company’s stock valued at $10,489,000 after acquiring an additional 761,685 shares during the period. OP Asset Management Ltd purchased a new position in Niagen Bioscience during the 1st quarter valued at about $1,475,000. Sei Investments Co. boosted its stake in Niagen Bioscience by 155.6% during the first quarter. Sei Investments Co. now owns 971,574 shares of the company’s stock worth $4,285,000 after acquiring an additional 591,495 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Niagen Bioscience by 45.4% in the first quarter. Renaissance Technologies LLC now owns 1,328,843 shares of the company’s stock worth $5,860,000 after purchasing an additional 414,725 shares during the period. Institutional investors own 15.41% of the company’s stock.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.